Abstract
Nanoparticles have shown great promise for improving the efficacy of nucleic acid drugs that lack permeability and bioavailability needed for reaching their intracellular site of action. The pharmacokinetics of the nucleic acid nanomedicines contributes greatly to their pharmacodynamic and toxicity characteristics. The pharmacokinetics of nanomedicines is determined by their physiochemical properties, such as particle size, shape, surface charge, and surface modifications. This review presented the pharmacokinetic and pharmacodynamic perspectives of nucleic acid nanomedicines. The cellular trafficking of the nucleic acid nanomedicines after cellular uptake is also discussed. In addition, the review puts forward potential strategies for circumventing biological barriers to delivering and releasing nucleic acid drugs into their intracellular site of action, and perspectives in this rapidly evolving field.
Keywords: Antisense oligonucleotide, gene therapy, intracellular trafficking, microRNA, nanomedicine, pharmacodynamic, pharmacokinetic, plasmid DNA, small interfering RNA.
Current Pharmaceutical Biotechnology
Title:Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Volume: 15 Issue: 9
Author(s): Chenguang Zhou, Zhaogang Yang and Lesheng Teng
Affiliation:
Keywords: Antisense oligonucleotide, gene therapy, intracellular trafficking, microRNA, nanomedicine, pharmacodynamic, pharmacokinetic, plasmid DNA, small interfering RNA.
Abstract: Nanoparticles have shown great promise for improving the efficacy of nucleic acid drugs that lack permeability and bioavailability needed for reaching their intracellular site of action. The pharmacokinetics of the nucleic acid nanomedicines contributes greatly to their pharmacodynamic and toxicity characteristics. The pharmacokinetics of nanomedicines is determined by their physiochemical properties, such as particle size, shape, surface charge, and surface modifications. This review presented the pharmacokinetic and pharmacodynamic perspectives of nucleic acid nanomedicines. The cellular trafficking of the nucleic acid nanomedicines after cellular uptake is also discussed. In addition, the review puts forward potential strategies for circumventing biological barriers to delivering and releasing nucleic acid drugs into their intracellular site of action, and perspectives in this rapidly evolving field.
Export Options
About this article
Cite this article as:
Zhou Chenguang, Yang Zhaogang and Teng Lesheng, Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/1389201015666141020155620
DOI https://dx.doi.org/10.2174/1389201015666141020155620 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives of New Therapies for Endometriosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Immunological Aspects of Metritis in Dairy Cows: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects
Recent Patents on Anti-Cancer Drug Discovery Lynch Syndrome: Awareness among Medical Students at a United States Medical School
Current Women`s Health Reviews Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Beta-glucans is a Potential Inhibitor of Ovarian Cancer: Based on Molecular and Biological Aspects
Current Pharmaceutical Biotechnology Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature
Current Pharmaceutical Design Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Physical Activity and Cancer Prevention: Updating the Evidence. The Role of Oxidative Stress in Carcinogenesis
Current Cancer Therapy Reviews Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry